NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only

Kinetic analysis of itravirion reverse transcription in the blood plasma of HIV-1-infected-Individuals: direct assessment of resistance to reverse transcriptase inhibitors in vivo.

Zhang H, Dornadula G, Wu Y, Havlir D, Richman DD, Pomerantz RJ; Conference on Retroviruses and Opportunistic Infections.

Program Abstr 3rd Conf Retrovir Oppor Infect Conf Retrovir Oppor Infect 3rd 1996 Wash D C. 1996 Jan 28-Feb 1; 3rd: 54.

The Dorrance H. Hamilton Laboratories, Section of Molecular Retrovirology, Thomas Jefferson University, 1020 Locust Street Philadelphia, PA.

Intravirion reverse transcripts have been identified in the blood plasma of human immunodeficiency virus type 1 (HIV-l)-infected-individuals. In the present studies, the kinetic processes of intravirion HIV-1 reverse transcription, in the blood plasma of HIV-1-infected persons treated with nevirapine, were investigated. Nevirapine is a non-nucleoside inhibitor of reverse transcriptase (RT) which decreases the level of HIV-1 viral particles in the blood plasma of infected-individuals. By analyzing HIV-1 virions at different time points prior to and after initiation of nevirapine therapy in vivo, the levels of intravirion reverse transcripts have been demonstrated to be dramatically susceptible to this anti-RT agent out of proportion to effects on plasma virion load. The intravirion reverse transcripts were also documented to rebound to the pre-treatment levels, concomitant with the development of resistant viral mutants. In addition, the infectivity of HIV-1 virions dramatically decreased after nevirapine treatment, further indicating that the effects of this anti-RT agent begin within the cell-free virions. As the levels of intravirion reverse transcripts were altered according to the susceptibility or resistance of the HIV-1 RT enzyme to this inhibitor, these data demonstrate that the formation of intravirion reverse transcripts is a dynamic process in vivo. Moreover, because the alteration in ratios between intravirion HIV-1 reverse transcripts and viral genomic RNA directly reflects the efficiency of reverse transcription, we propose that the determination of these ratios in the blood plasma of HIV-l-positive patients maybe a useful and, most importantly, a direct assay to monitor the efficacy of anti-RT agents in vivo.

Publication Types:
  • Meeting Abstracts
Keywords:
  • Acquired Immunodeficiency Syndrome
  • HIV Infections
  • HIV Seropositivity
  • HIV-1
  • Humans
  • Nevirapine
  • RNA, Viral
  • RNA-Directed DNA Polymerase
  • Resin Cements
  • Reverse Transcriptase Inhibitors
  • Reverse Transcription
  • Transcription, Genetic
  • Virion
  • genetics
  • methods
  • reverse transcriptase, Human immunodeficiency virus 1
Other ID:
  • 96920008
UI: 102216055

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov